Search

Your search keyword '"Campbell, Jonathan D."' showing total 438 results
Start Over Author "Campbell, Jonathan D."
438 results on '"Campbell, Jonathan D."'

1. Cost-Effectiveness of HIV Screening in Emergency Departments: Results From the Pragmatic Randomized HIV Testing Using Enhanced Screening Techniques in Emergency Departments Trial

Author

Austin, Bryan, Cohen, Jacob, Easley, Jackie, Haider, Somiya, Hill, Peter, Henley, Mauren, Kelen, Gabor, Leathers, Maggie, Maliszewski, Barbara, Neira, Paula, Newton, Scott, Peterson, Stephen, Saheed, Mustapha, Signer, Danielle, Spaeth, Lucas, Tolson, Tina, Toerper, Matthew, Viertel, Valentina, Whalen, Maddie, Ancona, Rachel, Cronin, Catherine, Fernandez, Frank, Fichtenbaum, Carl, Gaffney, Cortney, Hamilton, Cathy, Hart, Kim, Hoskins, Dave, Kohrs, Sharon, Lindsell, Christopher, Miller, Chris, Punches, Brittany, Ruffner, Andrew, Rowan, Geri, Vance, Kim, Williams, Teresa, Bucossi, Meggan, Cantrill, Steve, Chavez, Angelica, Comeau, Ann, Daugherty, Tracy, Delgado, Alex, Doyle, Pamela, Esquivel, Roberto, Fassino, Maren, Finnegan, Kelly, Fliney, Greg, Freudig, Theresa, Fuhriman, Michael, Gillman, Mary, Kahl-Geiger, Stacey, Keating, Korina, Koerner, Jason, Laber, Karen, Lang, Meghan, Lyle, Carolynn, Makela, Kim, Maltby, Mary, Medina, David, Nielsen, Tanya, Ortiz, Alice, Paolucci, Angela, Pate, Don, Pippins, Michael, Roy, Steven, Searcey, John, Solot, Jerry, Stermer, Kelly, Stuart, Brian, Swanson, Melissa, Timkovich, Lauren, Toure, Zenia, Vogel, Lisa, Walker, Sommer, Weed, Diane, Weise, Julia, Wenke, Kerri, Wham, Courtney, Wilson, Michael, Wright, Jarrod, Zwakenberg, Melody, Alter, Harrison, Anderson, Erik, Campbell, Brendan, Chang, Grace, Chao, Connie, Ellis, Katie, Graffman, Sarah, Kron, Brynn, Lucas, Rebecca, McCarthy, Caitlin, Ng, Valerie, O’Dell, Christine, Peck, Jim, Petti, Mae, Pfeil, Sarah, Saechao, Feuy, Simon, Barry, Todorovic, Tamara, Tyree, Tonya, Haukoos, Jason, Hopkins, Emily, Campbell, Jonathan D., Lyons, Michael S., Rothman, Richard E., Hsieh, Yu-Hsiang, White, Douglas A.E., Trent, Stacy, Al-Tayyib, Alia A., Gardner, Edward M., Sabel, Allison L., and Rowan, Sarah E.

Published
2024
Full Text
View/download PDF

3. Effect of State Immunization Information System Based Reminder/Recall for Influenza Vaccinations: A Randomized Trial of Autodialer, Text, and Mailed Messages

Author

Szilagyi, Peter G, Albertin, Christina S, Saville, Alison W, Valderrama, Rebecca, Breck, Abigail, Helmkamp, Laura, Zhou, Xinkai, Vangala, Sitaram, Dickinson, L Miriam, Tseng, Chi-Hong, Campbell, Jonathan D, Whittington, Melanie D, Roth, Heather, Rand, Cynthia M, Humiston, Sharon G, Hoefer, Dina, and Kempe, Allison

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Clinical Research, Cancer, Influenza, Immunization, Prevention, Vaccine Related, Prevention of disease and conditions, and promotion of well-being, 3.4 Vaccines, Good Health and Well Being, Adolescent, Child, Child, Preschool, Colorado, Humans, Immunization Programs, Infant, Influenza Vaccines, Influenza, Human, New York, Reminder Systems, Text Messaging, autodiale, influenza vaccine, reminder/recall, text message, Human Movement and Sports Sciences, Paediatrics and Reproductive Medicine, Pediatrics, Paediatrics
Abstract

ObjectiveTo evaluate the effect of different modalities of centralized reminder/recall (autodialer, text, mailed reminders) on increasing childhood influenza vaccination.Study designTwo simultaneous randomized clinical trials conducted from October 2017 to April 1, 2018, in New York State and Colorado. There were 61 931 children in New York (136 practices) and 23 845 children in Colorado (42 practices) who were randomized to different centralized reminder/recall modalities-4 arms in New York (autodialer, text, mailed, and no reminder control) and 3 arms in Colorado (autodialer, mailed, and no reminder control). The message content was similar across modalities. Up to 3 reminders were sent for intervention arms. The main outcome measure was receipt of ≥1 influenza vaccine.ResultsIn New York, compared with the control arm (26.6%), postintervention influenza vaccination rates in the autodialer arm (28.0%) were 1.4 percentage points higher (adjusted risk ratio, 1.06; 95% CI, 1.02-1.10), but the rates for text (27.6%) and mail (26.8%) arms were not different from controls. In Colorado, compared with the control arm (29.9%), postintervention influenza vaccination rates for the autodialer (32.9%) and mail (31.5%) arms were 3.0 percentage points (adjusted risk ratio, 1.08; 95% CI, 1.03-1.12) and 1.6 percentage points (adjusted risk ratio, 1.06; 95% CI, 1.02-1.10) higher, respectively. Compared with the control arm, the incremental cost per additional vaccine delivered was $20 (New York) and $16 (Colorado) for autodialer messages.ConclusionsCentralized reminder/recall for childhood influenza vaccine was most effective via autodialer, less effective via mail, and not effective via text messages. The impact of each modality was modest. Compared with no reminders, the incremental cost per additional vaccine delivered was also modest for autodialer messages.Trial registrationClinicalTrials.gov: NCT03294473 and NCT03246100.

Published
2020

4. Effect of State Immunization Information System Centralized Reminder and Recall on HPV Vaccination Rates

Author

Szilagyi, Peter, Albertin, Christina, Gurfinkel, Dennis, Beaty, Brenda, Zhou, Xinkai, Vangala, Sitaram, Rice, John, Campbell, Jonathan D, Whittington, Melanie D, Valderrama, Rebecca, Breck, Abigail, Roth, Heather, Meldrum, Megan, Tseng, Chi-Hong, Rand, Cynthia, Humiston, Sharon G, Schaffer, Stanley, and Kempe, Allison

Subjects
Paediatrics, Biomedical and Clinical Sciences, Sexually Transmitted Infections, Vaccine Related, Cancer, Prevention, HPV and/or Cervical Cancer Vaccines, Immunization, Clinical Trials and Supportive Activities, Infectious Diseases, Clinical Research, Pediatric, 3.4 Vaccines, Prevention of disease and conditions, and promotion of well-being, Infection, Good Health and Well Being, Adolescent, Child, Colorado, Female, Humans, Immunization Programs, Male, New York, Papillomavirus Infections, Papillomavirus Vaccines, Reminder Systems, Vaccination, Medical and Health Sciences, Psychology and Cognitive Sciences, Pediatrics, Biomedical and clinical sciences, Health sciences, Psychology
Abstract

Although autodialer centralized reminder and recall (C-R/R) from state immunization information systems (IISs) has been shown to raise childhood vaccination rates, its impact on human papillomavirus (HPV) vaccination rates is unclear. In a 4-arm pragmatic randomized controlled trial across 2 states, we randomly selected practices representative of the specialty (pediatrics, family medicine, and health center) where children received care. Within each practice, patients 11 to 17.9 years old who had not completed their HPV vaccine series (NY: N = 30 616 in 123 practices; CO: N = 31 502 in 80 practices) were randomly assigned to receive 0, 1, 2, or 3 IIS C-R/R autodialer messages per vaccine dose. We assessed HPV vaccine receipt via the IIS, calculated intervention costs, and compared HPV vaccine series initiation and completion rates across study arms. In New York, HPV vaccine initiation rates ranged from 37.0% to 37.4%, and completion rates were between 29.1% and 30.1%, with no significant differences across study arms. In Colorado, HPV vaccine initiation rates ranged from 31.2% to 33.5% and were slightly higher for 1 reminder compared with none, but vaccine completion rates, ranging from 27.0% to 27.8%, were similar. On adjusted analyses in Colorado, vaccine initiation rates were slightly higher for 1 and 3 C-R/R messages (adjusted risk ratios 1.07 and 1.04, respectively); completion rates were slightly higher for 1 and 3 C-R/R messages (adjusted risk ratios 1.02 and 1.03, respectively). IIS-based C-R/R for HPV vaccination did not improve HPV vaccination rates in New York and increased vaccination rates slightly in Colorado.

Published
2020

13. Effect of State Immunization Information System Based Reminder/Recall for Influenza Vaccinations: A Randomized Trial of Autodialer, Text, and Mailed Messages

Author

Szilagyi, Peter G., Albertin, Christina S., Saville, Alison W., Valderrama, Rebecca, Breck, Abigail, Helmkamp, Laura, Zhou, Xinkai, Vangala, Sitaram, Dickinson, L. Miriam, Tseng, Chi-Hong, Campbell, Jonathan D., Whittington, Melanie D., Roth, Heather, Rand, Cynthia M., Humiston, Sharon G., Hoefer, Dina, and Kempe, Allison

Published
2020
Full Text
View/download PDF

14. Value of Information in Asia: Concepts, Current Use, and Future Directions

Author

Dilokthornsakul, Piyameth, McQueen, R Brett, Chaiyakunapruk, Nathorn, Spackman, Eldon, Watanabe, Jonathan H, and Campbell, Jonathan D

Subjects
Economics, Applied Economics, Clinical Research, Health Services, Generic health relevance, Good Health and Well Being, Asia, Cost-Benefit Analysis, Decision Making, Economics, Pharmaceutical, Health Policy, Outcome Assessment, Health Care, Policy Making, Research Design, Technology Assessment, Biomedical, cost-effectiveness analysis, value of information, Pharmacology and Pharmaceutical Sciences, Public Health and Health Services, Applied economics, Health services and systems, Policy and administration
Abstract

Health technology assessment is a form of health policy research that provides policymakers with information relevant to decisions about policy alternatives. Findings from cost-effectiveness analysis (CEA) are one of the important aspects of health technology assessment. Nevertheless, the more advanced method of value of information (VOI), which is recommended by the International Society for Pharmacoeconomics and Outcomes Research and Society for Medical Decision Making Modeling Good Research Practices Task Force, has rarely been applied in CEA studies in Asia. The lack of VOI in Asian CEA studies may be due to limited understanding of VOI methods and what VOI can and cannot help policy decision makers accomplish. This concept article offers audiences a practical primer in understanding the calculation, presentation, and policy implications of VOI. In addition, it provides a rapid survey of health technology assessment guidelines and literature related to VOI in Asia and discusses the future directions of VOI use in Asia and its potential barriers. This article will enable health economists, outcomes researchers, and policymakers in Asia to better understand the importance of VOI analysis and its implications, leading to the appropriate use of VOI in Asia.

Published
2016

30. Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force

Author

Roche, Nicolas, Campbell, Jonathan D., Krishnan, Jerry A., Brusselle, Guy, Chisholm, Alison, Bjermer, Leif, Thomas, Mike, van Ganse, Eric, van den Berge, Maarten, Christoff, George, Quint, Jennifer, Papadopoulos, Nikolaos G., and Price, David

Published
2019
Full Text
View/download PDF

48. The prevalence of MS in the United States

Author

Wallin, Mitchell T., Culpepper, William J., Campbell, Jonathan D., Nelson, Lorene M., Langer-Gould, Annette, Marrie, Ruth Ann, Cutter, Gary R., Kaye, Wendy E., Wagner, Laurie, Tremlett, Helen, Buka, Stephen L., Dilokthornsakul, Piyameth, Topol, Barbara, Chen, Lie H., and LaRocca, Nicholas G.

Subjects
Article
Abstract

Objective To generate a national multiple sclerosis (MS) prevalence estimate for the United States by applying a validated algorithm to multiple administrative health claims (AHC) datasets. Methods A validated algorithm was applied to private, military, and public AHC datasets to identify adult cases of MS between 2008 and 2010. In each dataset, we determined the 3-year cumulative prevalence overall and stratified by age, sex, and census region. We applied insurance-specific and stratum-specific estimates to the 2010 US Census data and pooled the findings to calculate the 2010 prevalence of MS in the United States cumulated over 3 years. We also estimated the 2010 prevalence cumulated over 10 years using 2 models and extrapolated our estimate to 2017. Results The estimated 2010 prevalence of MS in the US adult population cumulated over 10 years was 309.2 per 100,000 (95% confidence interval [CI] 308.1–310.1), representing 727,344 cases. During the same time period, the MS prevalence was 450.1 per 100,000 (95% CI 448.1–451.6) for women and 159.7 (95% CI 158.7–160.6) for men (female:male ratio 2.8). The estimated 2010 prevalence of MS was highest in the 55- to 64-year age group. A US north-south decreasing prevalence gradient was identified. The estimated MS prevalence is also presented for 2017. Conclusion The estimated US national MS prevalence for 2010 is the highest reported to date and provides evidence that the north-south gradient persists. Our rigorous algorithm-based approach to estimating prevalence is efficient and has the potential to be used for other chronic neurologic conditions.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results